Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis
|
|
- Grant Gibbs
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10: Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis BARBARA BRADEN,* JOHNNY HALLIDAY,* SANJEEWA ARYASINGHA,* YALDA SHARIFI,* DAVIDE CHECCHIN,* BRYAN F. WARREN, TAYA KITIYAKARA,* SIMON P.L. TRAVIS,* and ROGER W. CHAPMAN* *Translational Gastroenterology Unit, and Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom This article has an accompanying continuing medical education activity on page e31. Learning Objective At the end of this activity, the learner will identify the risk for the development of colorectal neoplasia in patients with colonic Crohn s disease and concomitant primary sclerosing cholangitis compared to patients with ulcerative colitis and concomitant primary sclerosing cholangitis. Podcast interview: Also available on itunes. BACKGROUND & AIMS: Patients with ulcerative colitis and concomitant primary sclerosing cholangitis (PSC) have a greater risk of developing colorectal dysplasia or invasive cancer than patients with only ulcerative colitis. Therefore, annual surveillance colonoscopies are recommended. We investigated whether primary sclerosing cholangitis is also a risk factor for colorectal dysplasia or cancer in patients with Crohn s disease of the colon. METHODS: We performed a retrospective review of data from a tertiary care hospital on 166 patients with PSC and inflammatory bowel disease; 120 had concomitant ulcerative colitis, 35 had Crohn s disease, and 11 had indeterminate colitis. The controls comprised 114 patients with colonic involvement of Crohn s disease and 102 patients with ulcerative colitis. The main outcome parameter was the development of colorectal cancer or intraepithelial neoplasia. RE- SULTS: Only 1 patient with colonic Crohn s disease and concomitant PSC developed dysplasia in an adenomatous polyp during a median follow-up of 10 years (range, 7 16 years). In contrast, 2 cancers and 8 cases of colorectal dysplasia were diagnosed in patients with ulcerative colitis and PSC during a median follow up of 11 years (range, 8 16 years); the crude annual incidence of dysplasia or colorectal cancer was 1 in 150 patients with ulcerative colitis. Among patients with colonic Crohn s disease without PSC, 2 developed colorectal cancer during follow-up. The presence of PSC did not increase the risk of developing colorectal dysplasia in patients with Crohn s disease (P 1.00). CONCLUSIONS: PSC does not seem to increase the risk for dysplasia of the colon in patients with colonic Crohn s disease. Keywords: Inflammatory Bowel Syndrome; Colonoscopy; IBD; Screening. Patients with ulcerative colitis or colonic Crohn s disease are at increased risk of colorectal cancer. The classical risk factors include the extent and duration of inflammatory bowel disease, but a family history of sporadic colorectal cancer, the severity of histologic bowel inflammation over time, and coincidental colonic adenomas also seem to be independent risk factors. 1 Patients with ulcerative colitis and concomitant primary sclerosing cholangitis (PSC) have a significantly higher risk of developing colorectal intraepithelial neoplasia or invasive cancer than ulcerative colitis patients without PSC. The adjusted relative risk is reported to be from 3.1 to ,3 In a metaanalysis of 11 studies the risk for colorectal cancer was approximately fourfold increased in patients with ulcerative colitis and PSC compared with those with ulcerative colitis alone. 4 This is in spite of a clinical course of colitis in patients with ulcerative colitis and PSC that is commonly characterized by a quiescent colitis with relative rectal sparing and backwash ileitis. 5 It is unknown whether PSC also increases the risk of developing colorectal (pre)cancerous lesions in patients with colonic Crohn s disease. The lack of studies is explained by the rarity of PSC in the general population and the fact that ulcerative colitis is more commonly associated with PSC than Crohn s disease with colonic involvement, which is found in only 1% to 14% of all patients with PSC. 6 Dysplasia in inflammatory bowel disease is associated with concurrent or future colorectal cancer in ulcerative colitis and, although less investigated, also in Crohn s disease. 7 Therefore, dysplasia (intraepithelial neoplasia) is considered a marker of cancer risk in inflammatory bowel disease. Current colonoscopy surveillance programs in patients with longstanding inflammatory bowel syndrome of the colon aim to detect dysplasia in flat mucosa, or protruding lesions through random biopsies or by targeted biopsies after chromoendoscopy. Annual colonoscopy from the time of diagnosis of ulcerative colitis or Crohn s disease is recommended in patients with concomitant PSC. 8 In this retrospective study we investigated the occurrence of colorectal dysplasia or cancer in patients with colonic Crohn s disease with and without PSC and in patients with ulcerative colitis with and without PSC. Abbreviations used in this paper: CD, Crohn s disease; CI, confidence interval; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; UC, ulcerative colitis by the AGA Institute /$36.00 doi: /j.cgh
2 304 BRADEN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 10, No. 3 Table 1. Demographic Characteristics of Patients With IBD (and PSC) Diagnosis PSC and CD PSC and UC PSC and indeterminate colitis CD UC n Sex 19 m, 16 f 85 m, 35 f 6 m, 5 f 43 m, 71 f 68 m, 34 f Age (y) a 54 (36 66) 58 (50 69) 57 (25 64) 49 (38 65) 59 (46 68) Body weight (kg) a,b 67 (59 76) 80 (70 91) 66 (63 76) 68 (59 83) 80 (70 91) f, female; m, male. a Median (interquartile range). b At last visit. Methods Patients We studied 166 patients with PSC and colonic inflammatory bowel disease from our database of PSC patients treated in the John Radcliffe Hospital in Oxford. Only PSC patients with established diagnosis of Crohn s disease, ulcerative colitis, or indeterminate colitis were included. Patients with PSC without inflammatory bowel disease or inflammatory bowel disease of less than 5 years were not included in this study. Patients with duration of PSC of less than 3 years were also excluded. The diagnosis of PSC was based on established criteria in all patients (demonstration of characteristic multifocal stricturing and dilation of intrahepatic and/or extrahepatic bile ducts on cholangiography, in the presence of inflammatory bowel disease). The onset of PSC was designated as the date of the first abnormal liver histopathology, or cholangiography (endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography). One hundred twenty of the patients with PSC had concomitant ulcerative colitis, 35 had Crohn s disease with involvement of the colon (defined as at least 1 third of the colon affected by the disease), and 11 had indeterminate colitis. One hundred fourteen patients with colonic Crohn s disease without PSC and 102 patients with ulcerative colitis without PSC served as controls. Patients with duration of inflammatory bowel disease of less than 8 years were not included as controls. Controls were selected in consecutive alphabetical order from patients in the Oxford Inflammatory Bowel Disease (IBD) database. Patients with any pre-existing malignancy at the time of diagnosis of inflammatory bowel disease were not included. Controls with Crohn s colitis were matched according to age and extension of colitis to patients with PSC and Crohn s disease, patients with ulcerative colitis to patients with PSC and ulcerative colitis. All patients with PSC and inflammatory bowel disease were under an annual colonoscopy surveillance program. Patients with longstanding extensive inflammatory bowel disease of the colon without PSC were offered surveillance colonoscopy in 3- to 5-year intervals in accordance with current guidelines of the British Society of Gastroenterology. 8,9 Reasons for discontinuation of the colonoscopy surveillance were advanced age, poor health condition, subtotal or total colectomy, or death. Histopathology The Inflammatory Bowel Disease Dysplasia Study Group has established standard criteria for the diagnosis and grading of dysplasia. Dysplasia is defined as unequivocal neoplastic epithelial changes characterized by cytologic (eg, nuclear alterations, mitoses, mucin depletion) and architectural features (eg, mucosal thickening, crypt elongation and branching, nuclei pseudostratification). Using these criteria, colorectal biopsies were classified as negative, indefinite, or positive for dysplasia, with this latter group subdivided into low-grade and high-grade dysplasia. 10 According to the Vienna classification 11 invasive neoplasia was defined as neoplastic cellular proliferation extending into the lamina propria or muscularis mucosae (intramucosal carcinoma) or into the submucosal layer or beyond to the muscularis propria. Presence of dysplasia or cancer was always confirmed by a second pathologist. All the specimens with dysplastic or cancerous alterations were reviewed by an expert gastrointestinal histopathologist (BFW) with a special interest in inflammatory bowel disease and dysplasia. Statistics Data are shown as mean and standard deviation or median and interquartile range as appropriate. Differences between groups were compared using the Pearson Mantel Haenszel s 2 test. P.05 was considered statistically significant. 95% confidence intervals (CI) are given. Statistic analyses were performed using the program BIAS (version 7.06; epsilon verlag, Hochheim Darmstadt, Germany). Results Demographic characteristics of the patient groups with inflammatory bowel disease with and without PSC are given in Table 1. The majority of patients with PSC and inflammatory bowel disease were being treated with ursodeoxycholic acid at a daily dose of 15 to 20 mg/kg body weight; 74% of the patients with PSC and Crohn s disease, 82% of patients with PSC and indeterminate colitis, and 79% of the patients with PSC and ulcerative colitis received ursodeoxycholic acid (Table 2). Apart from 1 patient who developed a low grade adenomatous polyp in the descending colon and cecum, all other colorectal neoplastic lesions were observed in PSC patients taking ursodeoxycholic acid (P.28). Eighty-two percent of the patients with PSC and Crohn s disease had macroscopically a pancolitis, while in the patients with PSC and ulcerative colitis and indeterminate colitis, pancolitis was diagnosed in 89% and 73%, respectively. Ninety percent of the controls with ulcerative colitis and 75% of the controls with Crohn s disease had total colitis. From the 120 patients with ulcerative colitis and concomitant PSC, 1 developed a tubular adenoma with low grade dysplasia in the rectum. Seven patients were diagnosed with
3 March 2012 PSC AS A RISK FACTOR IN CROHN S DISEASE 305 Table 2. Follow-up in Patients With IBD and PSC Diagnosis PSC and CD PSC and UC PSC and indeterminate colitis Crohn s colitis UC n Patients receiving ursodeoxycholic 26 (74.3%) 95 (79.2%) 9 (81.8%) 0 0 acid Years of follow-up a For IBD 16 (9 25) 17 (11 27) 9 (8 15) 19 (12 26) 20 (14 29) For PSC 10 (7 16) 11 (8 16) 8 (5 10) NA NA Total years of follow-up For IBD For PSC NA NA Number of colonoscopies 3 (2 5) 4 (2 6) 2 (1.5 4) 3 (2 4) 4.5 (3 6) (Sub-)total colectomy Death PSC related NA NA Other causes Adenoma-like dysplastic lesion Nonadenoma-like dysplastic lesion 0 7 (2 indefinite) 0 (1 indefinite) 2 Colon cancer a Median (interquartile range). nonadenoma-like dysplastic lesions; 2 of these patients had dysplasia on 2 clearly separated biopsy areas. Two patients with ulcerative colitis and PSC developed cancer during the median follow up of 11 years (Table 2). The cumulative incidence rate of developing nonadenoma-like dysplasia or colorectal carcinoma was 7.5% (9/120) in patients with PSC and ulcerative colitis (Table 2). The crude annual incidence rate of dysplasia or colorectal cancer was 1 in 150 patients with PSC and ulcerative colitis. Among the 102 patients with ulcerative colitis alone, 1 was diagnosed with rectal cancer; in 2 others low grade dysplasia was detected. The odds ratio for PSC as risk factor for developing nonadenoma-like dysplastic lesions or colorectal cancer was 2.7 (95% CI, ) in patients with ulcerative colitis. Patients with adenoma-like dysplastic lesions were older (64 years, 54 71) than patients in whom nonadenoma-like dysplasia was found (38 years, 37 49; P.01). The only dysplasia observed during a median follow-up of 10 years in the 35 PSC patients with colonic involvement of Crohn s was an adenomatous polyp with dysplasia (Table 2). A 1-cm sized pedunculated polyp in the descending colon was removed using snare polypectomy in this patient. Histologically, it showed a tubular adenoma with low-grade dysplasia. In the 114 patients with Crohn s disease without PSC, 2 cancer, in the sigmoid colon and in the ascending colon, were diagnosed. A further case, indefinite dysplasia, was described in a biopsy from the anastomosis in a patient with previous ileocecal resection for complex Crohn s disease. Therefore, regarding PSC as an additional risk factor for developing dysplasia or colorectal cancer in patients with Crohn s colitis gives an odds ratio of 1.64 (95% CI, ). The characteristics of the patients with inflammatory bowel disease and concomitant PSC who developed colorectal cancer or dysplasia are given in Table 3. None of these patients had had liver transplantation. Only 5 of all 13 neoplastic lesions detected in patients with PSC were on the right side of the colon. Nonadenoma-like dysplastic lesions and colorectal cancer occurred more frequently in patients with ulcerative colitis and PSC (9/120) than in patients with Crohn s disease and PSC (0/35; P.07). Thirty of 120 (33%) patients with ulcerative colitis and PSC died during the follow-up time compared with 6 of 35 (17%) patients with Crohn s disease and PSC (P.33). PSC-related mortality occurred more frequently in patients with ulcerative colitis and PSC, but the difference was not significant (P.41; Table 2). In the control group of patients with Crohn s colitis without PSC, 2 patients died during the follow-up period, 1 from lung cancer, the other from myocardial infarction, none from cholangiocarcinoma. Discussion Despite evidence showing that PSC is a risk factor for colorectal cancer in patients with ulcerative colitis 4 and that there is increased risk of colorectal cancer in patients with Crohn s disease similar to longstanding ulcerative colitis, 12 it is unclear whether PSC is an additional risk factor for colorectal cancer in patients with Crohn s colitis. We have investigated this in the current study by comparing the prevalence of colorectal neoplasia in 5 groups of patients; patients with Crohn s colitis and PSC, patients with ulcerative colitis and PSC, patients with indeterminate colitis and PSC, and patients with Crohn s colitis or ulcerative pancolitis alone. Our data demonstrate no increased risk of colorectal neoplasia in patients with PSC and Crohn s colitis, in contrast to that found in patients with PSC and ulcerative colitis. The pathogenesis of the increased risk for colorectal cancer in patients with ulcerative colitis and PSC is unclear. Bile acids may be involved, as in patients with ulcerative colitis/psc, colorectal cancer is reported to occur predominantly in the right colon, 13 or associated with backwash ileitis, 14 where concentrations of secondary bile acids are thought to be highest. In addition, studies have demonstrated abnormal levels of fecal secondary bile acids in patients with colonic polyps and cancers
4 306 BRADEN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 10, No. 3 Table 3. Characteristics of Patients With PSC and UC or CD Who Developed Dysplasia or Colorectal Cancer Patient Age a (y), sex Follow-up in IBD a (y) UDCA intake Number of colonoscopies a Localization Extension of disease (Sub-)total colectomy Type of dysplasia or colorectal cancer UC 31 m 13 Yes 4 Rectum Pancolitis 2007 Adenocarcinoma UC 49 m 8 Yes 2 Rectum Left sided 1979 Low grade UC 72 m 4 Yes 2 Rectum Pancolitis No Low grade UC 35 m 2 Yes 2 Rectosigmoid Left sided 1989 Low grade UC 53 f 12 Yes 3 Sigmoid Pancolitis 2000 Adenocarcinoma (T3N2M0) UC 37 m 1 No 6 Descending Pancolitis No Low grade 57 m 20 Cecum Low grade UC 45 m 15 Yes 5 Cecum Pancolitis 1999 Low grade UC 24 m 3 Yes 4 Cecum Pancolitis 2004 Low grade 25 m 4 Rectosigmoid Low grade UC 37 f 15 Yes 4 Both in ascending Pancolitis 1997 Low and high grade UC 72 m 3 Yes 1 Rectum Pancolitis No Low grade in tubular adenomatous polyp Total UC 45 (35 56) 6 (3 14) 3.5 (2 4) 8 Left-sided 5 Right-sided 2 Cancer 10 Low grade 1 High grade CD 62 m 2 Yes 1 Descending Pancolitis No Low grade in tubular adenomatous polyp f, female; m, male; UDCA, ursodeoxycholic acid. a At time of detection of neoplasia. with 15 and without 16 inflammatory bowel disease. Moreover, studies 17 have shown ursodeoxycholic acid to be chemoprotective for colorectal neoplasia in patients with PSC and ulcerative colitis, while ursodeoxycholic acid has been shown to affect the bile salt pool composition by decreasing secondary bile salt levels. 18 However, interestingly in the present study, the dysplasia and cancer was predominantly left-sided, with only a minority of right-sided neoplasia in patients with PSC (5/14 cases). In a recent study by Thackeray et al, the colonic neoplasms that developed in patients with inflammatory bowel disease and PSC were spread throughout the colon. 19 Furthermore, if bile salts were that important, a higher incidence of colorectal cancer in patients with bile salt malabsorption (such as might occur after ileocaecal resection for Crohn s disease) might be expected. Ongoing genome-wide association studies in patients with PSC might find out whether genetic factors play a role and might shed some light on the special cancer risk observed in patients with PSC. Risk factors for the development of colorectal cancer in patients with ulcerative colitis, other than PSC, include long duration and extent of disease, 1 as well as severity of disease, 20 family history of colorectal cancer, 21 coincidental adenomas, and lack of regular mesalamine therapy. 22 Case reports describing colorectal cancer in Crohn s disease have historically compared risk factors and characteristics with those found in ulcerative colitis. 12 These series suggest similar risk factors in Crohn s disease for colorectal cancer development including long duration and extent of the disease. More recent evidence from studies of colorectal surveillance in patients with Crohn s colitis, 23 where the criteria for surveillance include involvement of more than a third of the colon, appear to confirm the increased risk in patients with Crohn s colitis. In contrast to ulcerative colitis, no previous studies have investigated the risk of additional PSC in colonic Crohn s disease. Rasmussen et al reported the development of 2 colorectal cancers in 9 patients with PSC and colonic Crohn s disease over a period of 15 years 24 which seems strikingly high compared with our data. In our study, only 1 of our 35 patients with PSC and Crohn s colitis developed a low-grade dysplastic tubular adenoma, which may itself have been coincidental to Crohn s colitis, during a follow-up of 10 years, or a cumulative 424 patient-years of follow-up. Sporadic adenomas (which are by definition dysplastic) can also develop in inflammatory bowel disease. Adenoma-like dysplasia-associated lesions (ALMs) should be distinguished from nonadenoma-like dysplasia-associated lesions or masses (DALMs) because the former are treated adequately by polypectomy with complete excision and continued endoscopic surveillance, 25 while the latter lead to consideration of colectomy. In our study, most dysplastic lesions and the 2 adenocarcinomas in patients with ulcerative colitis and PSC were in the left colon, which is in contrast to previous findings. 13 The predominance of left-sided (pre)malignant lesions in our study (9 of 14) might be due to the fact that most of our patients (78%) were treated with ursodeoxycholic acid whose chemoprotective effect might be greater on the right side of the colon due to pharmacologically higher concentrations. Patients with both inflammatory bowel disease and PSC are mostly endangered by the complications from end-stage liver disease. Whether screening colonoscopy can improve life expectancy is questionable, although this question remains unanswered even for patients with colitis, but without PSC. On the other hand, liver transplantation significantly extends the life expectancy of patients with PSC. However, PSC patients with a long history of pancolitis undergoing liver transplantation have an increased risk of developing colorectal cancer with reduced survival. 26,27 It is conceivable, therefore, that development of colorectal cancer has the potential to become a major cause of mortality in PSC patients. A recent cohort study by Claessen et al 28 reports a cumulative 10-year and 20-year risk of 14% and
5 March 2012 PSC AS A RISK FACTOR IN CROHN S DISEASE % in patients with PSC and concomitant inflammatory bowel disease for colorectal cancer. In contrast to previous studies, the risk was substantially higher than that of cholangiocarcinoma. The retrospective nature of the study does not allow us to confirm or assess other risk factors in our study population. Whether they had a family history of colorectal cancer or were on mesalamine therapy was not determined. There is, however, no evidence for the benefit of sulfasalazine and mesalamine in decreasing the rate of colorectal cancer in patients with PSC. Lindberg et al 13 did not show any chemoprotective effect of sulfasalazine in patients with PSC. Whether sulfasalazine is less effective than other mesalamines 29 or the mechanism of carcinogenesis in patients with PSC predominantly involves toxic bile acids and differs from those in ulcerative colitis alone, is not clear. The incidence of colorectal cancer in ulcerative colitis remains subject to debate, but appears to be lower than previously estimated. In a meta-analysis largely of studies from referral centers, the cumulative incidence of colorectal cancer in ulcerative colitis was 2% at 10-year, 8% at 20-year, and 18% at 30-year follow-up. 30 More recent population-based publications describe a lower cumulative risk of cancer with 1.1%, %, 32 or 5.4% 33 after a disease duration of 20 years which is more consistent with our findings. The lower incidence of colorectal neoplasia in inflammatory bowel disease in the last decade might also be explained by a higher proportion of patients on maintenance therapy with mesalamine, or azathioprine, and biological agents. In the last decade, advances in endoscopic imaging techniques using high definition endoscopes and chromoendoscopy have improved the detection rate for subtle dysplastic lesions. 34,35 The rate of dysplasia found in early colonoscopies may therefore be an underestimate, particularly when compared with those nowadays in patients with PSC undergoing annual colonoscopy using the best imaging techniques. The number of colonoscopies performed in patients with Crohn s colitis did not differ significantly from those with ulcerative colitis. Surveillance in Crohn s colitis has been recommended by many guidelines to match those with ulcerative colitis of a similar extent and duration. Not all gastroenterologists, however, offer surveillance to such patients, indicating that they are unconvinced of the effectiveness of such strategy. No cost-effective analysis on surveillance for patients with Crohn s colitis has been performed and it may be more effective to limit surveillance to those patients with additional risk factors, such as family history of colorectal cancer. In conclusion, the presence of primary sclerosing cholangitis in patients with colonic Crohn s disease does not seem to increase the risk of developing dysplasia of the colon as it does in patients with ulcerative colitis. Prospective studies are needed to confirm our findings. Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at and at doi: /j.gastro References 1. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006;35: Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94: Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007;102: Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56: Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54: Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26: Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn s colitis: a retrospective comparative study with ulcerative colitis. Histopathology 2007;50: Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59: Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60: Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14: Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47: Friedman S. Cancer in Crohn s disease. Gastroenterol Clin North Am 2006;35: Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001;44: Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120: Hill MJ, Melville DM, Lennard-Jones JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987;2: Stadler J, Yeung KS, Furrer R, et al. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988;38: Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124: Batta AK, Salen G, Holubec H, et al. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal watersoluble fraction after feeding to rats with colon polyps. Cancer Res 1998;58: Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9: Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53: Askling J, Dickman PW, Karlén P, et al. Family history as a risk
6 308 BRADEN ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 10, No. 3 factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120: Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100: Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 2008;6: ; Quiz: Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn s disease. Scand J Gastroenterol 1997;32: Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2: Ho GT, Seddon AJ, Therapondos G, et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005;17: Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003;75: Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50: van Staa TP, Card T, Logan RF, et al. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54: Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48: Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2: Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130: Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006;12: Hurlstone DP, Kiesslich R, Thomson M, et al. Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. Gut 2008;57: Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: Reprint requests Address requests for reprints to: Roger W. Chapman, MD, Department of Gastroenterology, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom. roger.chapman@ndm.ox.ac.uk; fax: (44) Conflicts of interest The authors disclose no conflicts.
Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationCRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1
Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and
More informationChromoendoscopy and Endomicroscopy for detecting colonic dysplasia
Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia Ralf Kiesslich I. Medical Department Johannes Gutenberg University Mainz, Germany Cumulative cancer risk in ulcerative colitis 0.5-1.0%
More informationIBD high risk groups
IBD high risk groups Ulcerative colitis Value (95% CI) CRC prevalence (%) 3.7 (3.2-4.2) Overall annual CRC incidence (%) 0.3 (0.2-0.4) Annual CRC incidence in first decade of UC (%) 0.2 (0.1-0.2) Annual
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Patients with Endoscopically Visible Polypoid Adenomatous Lesions Within the Extent of Ulcerative Colitis Have an Increased Risk of Colorectal Cancer Despite Endoscopic Resection.
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationDiagnostic techniques for surveillance of dysplasia
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Diagnostic techniques for surveillance of dysplasia Gerhard Rogler, Department of Gastroenterology
More informationThe variable risk of colorectal cancer in patients with inflammatory bowel disease.
The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01
More informationColorectal Cancer in Inflammatory Bowel Disease
Gut and Liver, Vol. 2, No. 2, September 2008, pp. 61-73 review Colorectal Cancer in Inflammatory Bowel Disease Jonathan Potack and Steven H. Itzkowitz Division of Gastroenterology, Department of Medicine,
More informationPatients with longstanding ulcerative colitis (UC) or
ORIGINAL ARTICLE Misclassification of Dysplasia in Patients with Inflammatory Bowel Disease: Consequences for Progression Rates to Advanced Neoplasia Fiona D.M. van Schaik, MD,* Fiebo J.W. ten Kate, MD,
More informationRandom biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis
Journal of Crohn's and Colitis (2013) 7, 974 981 Available online at www.sciencedirect.com ScienceDirect Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationAdvances in Ulcerative Colitis - Volume 3 CME
1 de 12 22/01/2008 04:46 p.m. More: Advances in Ulcerative Colitis Advances in Ulcerative Colitis - Volume 3 CME Complete author affiliations and disclosures are at the end of this activity. Release Date:
More informationPrimary sclerosing cholangitis (PSC) is a chronic, cholestatic
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:540 546 Progressive Primary Sclerosing Cholangitis Requiring Liver Transplantation Is Associated With Reduced Need for Colectomy in Patients With Ulcerative
More informationNew Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients
New Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients Toshiaki Watanabe, M.D., Ph.D. Department of Surgery, Teikyo University School of Medicine,
More informationMINI-REVIEW. Should we Sound the Alarm? Dysplasia and Colitis-associated Colorectal Cancer. Lin-Lin Ren, Jing-Yuan Fang * Abstract.
Should we Sound the Alarm?- Dysplasia and Colitis-associated Colorectal Cancer MINI-REVIEW Should we Sound the Alarm? Dysplasia and Colitis-associated Colorectal Cancer Lin-Lin Ren, Jing-Yuan Fang * Abstract
More informationDiagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease
Diagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease Francis A. Farraye, MD, MSc Clinical Director, Section of Gastroenterology, Boston Medical Center Professor of Medicine,
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationHow to characterize dysplastic lesions in IBD?
How to characterize dysplastic lesions in IBD? Name: Institution: Helmut Neumann, MD, PhD, FASGE University Medical Center Mainz What do we know? Patients with IBD carry an increased risk of developing
More informationAGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
GASTROENTEROLOGY 2010;138:746 774 AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease AGA Podcast interview: www.gastro.org/gastropodcast. Learning
More informationRole of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer
ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.3.264 Intest Res 2016;14(3):264-269 Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients
More informationMalignancy in ulcerative colitis (UC) is believed to ORIGINAL ARTICLES
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:534 541 ORIGINAL ARTICLES Long-term Follow-up After Polypectomy Treatment for Adenoma-Like Dysplastic Lesions in Ulcerative Colitis ROBERT D. ODZE,* FRANCIS
More informationComparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn s disease
Gastroenterology Report, 4(1), 2016, 43 49 doi: 10.1093/gastro/gou074 Advance Access Publication Date: 29 October 2014 Original article ORIGINAL ARTICLE Comparison of outcomes for patients with primary
More informationColorectal cancer surveillance in inflammatory bowel diseases
Turkish Journal of Cancer Volume 34, No.2, 2004 55 Colorectal cancer surveillance in inflammatory bowel diseases MURAT TÖRÜNER Ankara University Medical School, Department of Gastroenterology, Ankara-Turkey
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationCASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD
CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant
More informationChromoendoscopy - Should It Be Standard of Care in IBD?
Chromoendoscopy - Should It Be Standard of Care in IBD? John F. Valentine, MD, FACG Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Utah What is the point of
More informationChromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis
Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Bret A. Lashner, M.D. Professor of Medicine Director,
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationEndoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.
F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann@em.uni-frankfurt.de Indications for endoscopy Diagnosis Management Surveillance Diagnosis Single most valuable tool: ileocolonoscopy
More informationPatients with long-standing, extensive ulcerative colitis (UC) Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1225 1230 Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine THOMAS ULLMAN,* VICTORIA CROOG,* NOAM HARPAZ, SABERA HOSSAIN, ASHER
More informationWhen and How to use Chromoendoscopy in IBD
When and How to use Chromoendoscopy in IBD Samir A. Shah, MD, FACG, FASGE, AGAF Clinical Professor of Medicine, Brown University Chief of Gastroenterology, The Miriam Hospital Gastroenterology Associates,
More informationReview Article Chronic Inflammation and Malignancy in Ulcerative Colitis
Ulcers Volume 2011, Article ID 714046, 8 pages doi:10.1155/2011/714046 Review Article Chronic Inflammation and Malignancy in Ulcerative Colitis Sai Sunkara, 1 Garth Swanson, 2 Christopher B. Forsyth, 2
More informationDiagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases
Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department
More informationIntestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines
INVITED REVIEW Annals of Gastroenterology (2012) 25, 1-8 Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines Vicent Hernández a, Juan Clofent b Complexo Hospitalario
More informationChromoendoscopy as an Adjunct to Colonoscopy
Chromoendoscopy as an Adjunct to Colonoscopy Policy Number: 2.01.84 Last Review: 1/2018 Origination: 7/2017 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More informationC olorectal cancer (CRC) is one of the most feared
1573 INFLAMMATORY BOWEL DISEASE 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study T P van Staa, T Card, R F Logan, H G M Leufkens... See end
More informationBENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES
Medical Policy BCBSA Ref. Policy: 2.01.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/Computed
More informationAdherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn s colitis patients in the Netherlands
Online Submissions: wjg.wjgnet.com World J Gastroenterol 9 January 14; 15(2): 226-23 wjg@wjgnet.com World Journal of Gastroenterology ISSN 17-9327 doi:1.3748/wjg.15.226 9 The WJG Press and Baishideng.
More informationPatients with inflammatory bowel disease (IBD) carry a higher
Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease Shirley Cohen-Mekelburg, MD, Yecheskel Schneider, MD, Stephanie Gold, MD, Ellen Scherl, MD, and
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationUSCAP Companion Meeting 2006 Arthur Purdy Stout Society of Surgical Pathology Sporadic Adenomas and DALMs in IBD
1 USCAP Companion Meeting 2006 Arthur Purdy Stout Society of Surgical Pathology Sporadic Adenomas and DALMs in IBD Robert D Odze, M.D., FRCP(c) Chief, Gastrointestinal Pathology Service Associate Professor
More informationP rimary sclerosing cholangitis (PSC) is a chronic cholestatic
91 INFLAMMATORY BOWEL DISEASE PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis E V Loftus Jr, G C Harewood, C G Loftus, W J Tremaine, W S Harmsen, A R
More informationIncreased Risk of Primary Sclerosing Cholangitis and Ulcerative Colitis in First-Degree Relatives of Patients With Primary Sclerosing Cholangitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:939 943 Increased Risk of Primary Sclerosing Cholangitis and Ulcerative Colitis in First-Degree Relatives of Patients With Primary Sclerosing Cholangitis
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationRomanian Journal of Morphology and Embryology 2006, 47(3):
Romanian Journal of Morphology and Embryology 26, 7(3):239 23 ORIGINAL PAPER Predictive parameters for advanced neoplastic adenomas and colorectal cancer in patients with colonic polyps a study in a tertiary
More informationHyperplastische Polyps Innocent bystanders?
Hyperplastische Polyps Innocent bystanders?? K. Geboes P th l i h O tl dk d Pathologische Ontleedkunde, KULeuven Content Historical Classification Relation Hyperplastic polyps carcinoma The concept cept
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationInflammatory bowel disease (IBD), which includes ulcerative
Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future Steven Naymagon, MD, and Thomas A. Ullman, MD Dr Naymagon is an assistant professor of medicine and Dr
More informationNovel Optical Research at UPMC
Novel Optical Research at UPMC Randall Brand, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Pittsburgh Medical Center Background Patients with UC and CD of
More informationThere is a well-established association between inflammatory
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1346 1350 Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis DAVID T. RUBIN, ANDELKA LOSAVIO, NICOLE YADRON,
More informationI n 1925, Crohn and Rosenberg first observed that ulcerative
256 INFLAMMATORY BOWEL DISEASE Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis M D Rutter, B P Saunders, G Schofield, A Forbes, A B Price, I C Talbot... See
More informationPrimary sclerosing cholangitis and primary biliary cirrhosis: epidemiology, risk factors, and outcome Boonstra, K.
UvA-DARE (Digital Academic Repository) Primary sclerosing cholangitis and primary biliary cirrhosis: epidemiology, risk factors, and outcome Boonstra, K. Link to publication Citation for published version
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationIBD. Crohn s. Outline. Ulcerative colitis versus Crohn s disease: is biopsy useful? UC vs. Crohn s? Is it easy? Biopsy settings 21/07/2017 IBD
Outline Ulcerative colitis versus Crohn s disease: is biopsy useful? Roger Feakins Colorectal biopsies Ileal and upper GI biopsies Special situations New techniques Summary Inflammatory bowel disease (IBD)
More informationChromoscopy-Guided Endomicroscopy Increases the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative Colitis
GASTROENTEROLOGY 2007;132:874 882 Chromoscopy-Guided Endomicroscopy Increases the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative Colitis RALF KIESSLICH,* MARTIN GOETZ,* KATHARINA LAMMERSDORF,*
More informationThe Importance of Complete Colonoscopy and Exploration of the Cecal Region
The Importance of Complete Colonoscopy and Exploration of the Cecal Region Kuangi Fu, Takahiro Fujii, Takahisa Matsuda, and Yutaka Saito 2 2.1 The Importance of a Complete Colonoscopy Ever since case-control
More informationQuality Measures In Colonoscopy: Why Should I Care?
Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationPatho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology
Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease
More informationImaging Evaluation of Polyps. CT Colonography: Sessile Adenoma. Polyps, DALMs & Megacolon Objectives
Polyps, DALMs & Megacolon: Pathology and Imaging of the Colon and Rectum Angela D. Levy and Leslie H. Sobin Washington, DC Drs. Levy and Sobin have indicated that they have no relationships which, in the
More informationThe Natural History of Small-Duct Primary Sclerosing Cholangitis
GASTROENTEROLOGY 2008;134:975 980 The Natural History of Small-Duct Primary Sclerosing Cholangitis EINAR BJÖRNSSON,* ROLF OLSSON,* ANNIKA BERGQUIST, STEFAN LINDGREN, BARBARA BRADEN, ROGER W. CHAPMAN, KIRSTEN
More informationQuality in Endoscopy: Can We Do Better?
Quality in Endoscopy: Can We Do Better? Erik Rahimi, MD Assistant Professor Division of Gastroenterology, Hepatology, and Nutrition UT Health Science Center at Houston McGovern Medical School Ertan Digestive
More informationHigh frequency of early colorectal cancer in inflammatory bowel disease
See Commentary, p 1194 1 Department of Hepatology, University Medical Center, Utrecht, The Netherlands; 2 Department of Pathology, University Medical Center, Utrecht, The Netherlands; 3 Department of Hepatology,
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationMorphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens
ISPUB.COM The Internet Journal of Pathology Volume 12 Number 1 Morphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens C Rose, H Wu Citation C Rose, H Wu.. The Internet Journal of Pathology.
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More informationPatterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis A Retrospective Study of 46 Newly Diagnosed Cases
Anatomic Pathology / PATTERNS OF INVOLVEMENT IN ULCERATIVE COLITIS Patterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis A Retrospective Study of 46 Newly Diagnosed Cases Marie
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationChemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1015 1021 Chemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine SIERRA MATULA,* VICTORIA CROOG,* STEVEN ITZKOWITZ,*
More informationLow-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
nature publishing group ORIGINAL CONTRIBUTIONS 1461 CME see related editorial on page 1473 Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
More informationSynchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum
Tsumura T, et al 1 Synchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum T. Tsumura a T. Hiyama d S. Tanaka b M. Yoshihara d K. Arihiro c K. Chayama a Departments
More informationPrimary Sclerosing Cholangitis with Inflammatory Bowel Disease in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2015.18.4.268 Pediatr Gastroenterol Hepatol Nutr 2015 December 18(4):268-275 Original Article PGHN Primary Sclerosing Cholangitis with Inflammatory
More informationSAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #
SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST Ver. #5-02.12.17 GUIDELINES FOR DEVELOPING SELF-ASSESSMENT MODULES TEST The USCAP is accredited by the American Board of Pathology (ABP) to offer
More informationSurgical Procedure for Sporadic Colorectal Cancer in Patients with Mild Ulcerative Colitis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationColorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease and polyps
Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease and polyps Full guideline Draft for consultation, May 00 0 This guideline
More informationExpert panel observations
Expert panel observations Professor Neil A Shepherd Gloucester and Cheltenham, UK Gloucestershire Cellular Pathology Laboratory Three big issues in BCSP pathology serrated pathology & what do we do about
More informationManagement of pt1 polyps. Maria Pellise
Management of pt1 polyps Maria Pellise Early colorectal cancer Malignant polyp Screening programmes SM Invasive adenocar cinoma Advances in diagnostic & therapeutic endoscopy pt1 polyps 0.75 5.6% of large-bowel
More informationFrequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema
Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To
More informationTitle: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease
Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease Authors: Jesús Castro, Miriam Cuatrecasas, Francesc Balaguer, Elena Ricart, María Pellisé DOI: 10.17235/reed.2017.5068/2017
More informationConfocal Laser Endomicroscopy of the Colon
clinical imaging Confocal Laser Endomicroscopy of the Colon Dan Ionut Gheonea, Adrian Saftoiu, Tudorel Ciurea, Carmen Popescu, Claudia Valentina Georgescu, Anca Malos Research Center of Gastroenterology
More informationMeta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis
Alimentary Pharmacology & Therapeutics Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis T. THOMAS*, K. A. ABRAMS, R.J.ROBINSON*&J.F.MAYBERRY* *Department of Gastroenterology,
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationThe pathology of IBD and its modification by liver disease. Roger Feakins ESP/H-ECCO
The pathology of IBD and its modification by liver disease Roger Feakins ESP/H-ECCO Enterprise Interest None IBD UC [IBDU] Crohn s IBD: distribution of disease Ulcerative colitis continuous Crohn s colitis
More informationValue of sigmoidoscopy and biopsy in detection of
Gut, 1979, 20, 575-580 Value of sigmoidoscopy and biopsy in detection of carcinoma and premalignant change in ulcerative colitis R. H. RIDDELL' AND B. C. MORSON From the Department ofpathology, St. Marks
More informationPitfalls in the Diagnosis of Inflammatory Bowel Disease
Pitfalls in the Diagnosis of Inflammatory Bowel Disease Robert H Riddell MD Mt Sinai Hospital Toronto Prof of Lab. Medicine and Pathobiology University of Toronto Atypical gross / endoscopic distribution
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
More informationReview Histological evaluation in ulcerative colitis
Gastroenterology Report 2 (2014) 178 192, doi:10.1093/gastro/gou031 Advance access publication 18 June 2014 Review Histological evaluation in ulcerative colitis Tom C. DeRoche 1, Shu-Yuan Xiao 2 and Xiuli
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationIN THE DEVELOPMENT and progression of colorectal
Digestive Endoscopy 2014; 26 (Suppl. 2): 73 77 doi: 10.1111/den.12276 Treatment strategy of diminutive colorectal polyp
More informationInflammatory bowel disease (IBD) patients have a higher risk of
Serrated Colorectal Lesions in Patients With Inflammatory Bowel Disease Alyssa M. Parian, MD, and Mark G. Lazarev, MD Dr Parian and Dr Lazarev are assistant professors of medicine at Johns Hopkins University
More informationCOLON: Innovations 3 steps, 3 parts..
COLON: Innovations 3 steps, 3 parts.. Detection: I see an abnormality (usually a polyp) Characterization: Is this abnormality neoplastic? (for example: an adenoma) Treatment: it is neoplastic. Can I treat
More informationINTERNATIONAL COURSE ON THE PATHOLOGY OF THE DIGESTIVE SYSTEM VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY BUCHAREST 7-8 BUCHAREST 2014
INTERNATIONAL COURSE ON THE PATHOLOGY OF THE DIGESTIVE SYSTEM VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY BUCHAREST 7-8 BUCHAREST 2014 Endoscopic biopsy samples of naïve colitides patients: Role of basal
More informationMasato Kusunoki Editor. Colitis-Associated Cancer
Masato Kusunoki Editor Colitis-Associated Cancer 123 Colitis-Associated Cancer ThiS is a FM Blank Page Masato Kusunoki Editor Colitis-Associated Cancer Editor Masato Kusunoki Mie University Graduate School
More information